Overview

• Commerce and Industry Minister Piyush Goyal said no evidence exists of Indian firms illegally copying Swiss pharma trademarks, patents or technology.
• He underscored that under Section 3(d) of the Patents Act, Indian law prohibits patent evergreening by limiting extensions on minor drug modifications.
• Goyal highlighted regulatory reforms that streamline IP approval processes, reduce compliance burdens and accelerate patent filings.
• Swiss and other EFTA pharmaceutical companies provided input on the India-EFTA trade pact, and their suggestions have been integrated into the new IP framework.
• India’s 1.4 billion–strong market is positioned as a partner for delivering affordable medicines and strengthening ties with global drugmakers.